About Us
We are on a mission to preserve vision and prevent blindness.
About Us
Qlaris Bio is a clinical-stage biotechnology company developing first-in-class therapies for unmet needs in ophthalmology. The Company’s lead candidate, QLS-111, is designed to treat glaucoma by targeting episcleral venous pressure and improving ocular perfusion.
QLS-111 is a novel vasodilatory topical ATP-sensitive potassium channel modulator designed to reduce intraocular pressure by lowering episcleral venous pressure. Originally discovered at Mayo Clinic, QLS-111 was developed by Qlaris Bio into a preservative-free eye-drop formulation. In Phase 2 clinical trials (Osprey and Apteryx), QLS-111 demonstrated sustained intraocular pressure reduction with a favorable safety profile.
Our Team
Board of Directors
Wende Hutton
Ron Hunt (Chair)
Andrew Danielsen
Adrienne Graves
Robert Warner
Scientific Advisory Board
Michael Fautsch, PhD (Chair)
Peter Farina, PhD
Alon Harris, MS, PhD, FARVO
Shan Lin, MD
Janet Serle, MD
Dan Stamer, PhD, FARVO
Carol Toris, PhD
Alex Huang, MD, PhD
Arthur Sit, MD, MS
Strategic Advisor
Vicente Anido
Investors
